Schiel R, Beltschikow W, Steiner T, Stein G: Diabetes, insulin, and risk of cancer. Methods Find Exp Clin Pharmacol. 2006, 28: 169-175. 10.1358/mf.2006.28.3.985230.
Article
CAS
PubMed
Google Scholar
Khan M, Mori M, Fujino Y, Shibata A, Sakauchi F, Washio M, Tamakoshi A: Site-specific cancer risk due to diabetes mellitus history: evidence from the Japan Collaborative Cohort (JACC) Study. Asian Pac J Cancer Prev. 2006, 7: 253-259.
PubMed
Google Scholar
Rosenberg DJ, Neugut AI, Ahsan H, Shea S: Diabetes mellitus and the risk of prostate cancer. Cancer Invest. 2002, 20: 157-165. 10.1081/CNV-120001141.
Article
PubMed
Google Scholar
Gonzalez-Perez A, Garcia Rodriguez LA: Prostate cancer risk among men with diabetes mellitus (Spain). Cancer Causes Control. 2005, 16: 1055-1058. 10.1007/s10552-005-4705-5.
Article
CAS
PubMed
Google Scholar
Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE: Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol. 2005, 161: 147-152. 10.1093/aje/kwh334.
Article
PubMed
Google Scholar
Cheng AY, Fantus IG: Oral antihyperglycemic therapy for type 2 diabetes mellitus. Can Med Assoc J. 2005, 172: 213-226. 10.1503/cmaj.1031414.
Article
Google Scholar
Savkur RS, Miller AR: Investigational PPAR-gamma agonists for the treatment of Type 2 diabetes. Expert Opin Investig Drugs. 2006, 15: 763-778. 10.1517/13543784.15.7.763.
Article
CAS
PubMed
Google Scholar
Todd MK, Watt MJ, Le J, Hevener AL, Turcotte LP: Thiazolidinediones enhance skeletal muscle triacylglycerol synthesis while protecting against fatty acid-induced inflammation and insulin resistance. Am J Physiol Endocrinol Metab. 2007, 292: E485-493. 10.1152/ajpendo.00080.2006.
Article
CAS
PubMed
Google Scholar
Wilding J: Thiazolidinediones, insulin resistance and obesity: finding a balance. Int J Clin Pract. 2006, 60: 1272-1280. 10.1111/j.1742-1241.2006.01128.x.
Article
CAS
PubMed
Google Scholar
Boden G, Zhang M: Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin Investig Drugs. 2006, 15: 243-250. 10.1517/13543784.15.3.243.
Article
CAS
PubMed
Google Scholar
Nunez M, Martin G, Cocca C, Mohamad N, Gutierrez A, Cricco G, Medina V, Rivera E, Croci M, Crescenti E, et al: Effect of rosiglitazone on N-nitroso-N-methylurea-induced mammary tumors in rat. Anticancer Res. 2006, 26: 2113-2122.
CAS
PubMed
Google Scholar
Russu WA: Thiazolidinedione anti-cancer activity: is inhibition of microtubule assembly implicated?. Med Hypotheses. 2007, 68: 343-346. 10.1016/j.mehy.2006.06.054.
Article
CAS
PubMed
Google Scholar
Chang AJ, Song DH, Wolfe MM: Attenuation of peroxisome proliferator-activated receptor gamma (PPARgamma) mediates gastrin-stimulated colorectal cancer cell proliferation. J Biol Chem. 2006, 281: 14700-14710. 10.1074/jbc.M602623200.
Article
CAS
PubMed
Google Scholar
Grommes C, Landreth GE, Sastre M, Beck M, Feinstein DL, Jacobs AH, Schlegel U, Heneka MT: Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. Mol Pharmacol. 2006, 70: 1524-1533. 10.1124/mol.106.022194.
Article
CAS
PubMed
Google Scholar
Han S, Roman J: Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Mol Cancer Ther. 2006, 5: 430-437. 10.1158/1535-7163.MCT-05-0347.
Article
CAS
PubMed
Google Scholar
Li MY, Lee TW, Yim AP, Chen GG: Function of PPARgamma and its ligands in lung cancer. Crit Rev Clin Lab Sci. 2006, 43: 183-202. 10.1080/10408360600552587.
Article
PubMed
Google Scholar
Martelli ML, Iuliano R, Le Pera I, Sama I, Monaco C, Cammarota S, Kroll T, Chiariotti L, Santoro M, Fusco A: Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab. 2002, 87: 4728-4735. 10.1210/jc.2001-012054.
Article
CAS
PubMed
Google Scholar
Yu J, Qiao L, Zimmermann L, Ebert MP, Zhang H, Lin W, Rocken C, Malfertheiner P, Farrell GC: Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology. 2006, 43: 134-143. 10.1002/hep.20994.
Article
CAS
PubMed
Google Scholar
Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA, Evans RM: Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med. 1998, 4: 1058-1061. 10.1038/2042.
Article
CAS
PubMed
Google Scholar
Seargent JM, Yates EA, Gill JH: GW a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. Br J Pharmacol. 9662, 143: 933-937. 10.1038/sj.bjp.0705973.
Article
Google Scholar
Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ, Lang NP: Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol. 2007, 25: 1476-1481. 10.1200/JCO.2006.07.2777.
Article
CAS
PubMed
Google Scholar
MacLean CD, Littenberg B, Gagnon M, Reardon M, Turner PD, Jordan C: The Vermont Diabetes Information System (VDIS): study design and subject recruitment for a cluster randomized trial of a decision support system in a regional sample of primary care practices. Clin Trials. 2004, 1: 532-544. 10.1191/1740774504cn051oa.
Article
PubMed
PubMed Central
Google Scholar
Gill SC, Butterworth P, Rodgers B, Mackinnon A: Validity of the mental health component scale of the 12-item Short-Form Health Survey (MCS-12) as measure of common mental disorders in the general population. Psychiatry Res. 2007.
Google Scholar
Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN: The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum. 2003, 49: 156-163. 10.1002/art.10993.
Article
PubMed
Google Scholar
Tamborlane WV, Kollman C, Steffes MW, Ruedy KJ, Dongyuan X, Beck RW, Chase P, Fox LA, Wilson DM, Tsalikian E: Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a Diabetes Research in Children Network (DirecNet) Study. Pediatr Diabetes. 2005, 6: 13-16. 10.1111/j.1399-543X.2005.00088.x.
Article
PubMed
Google Scholar
MacLean CD, Littenberg B, Kennedy AG: Limitations of diabetes pharmacotherapy: results from the Vermont Diabetes Information System study. BMC Fam Pract. 2006, 7: 50-10.1186/1471-2296-7-50.
Article
PubMed
PubMed Central
Google Scholar
Berria R, Gastaldelli A, Lucidi S, Belfort R, De Filippis E, Easton C, Brytzki R, Cusi K, Jovanovic L, DeFronzo R: Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. Clin Pharmacol Ther. 2006, 80: 105-114. 10.1016/j.clpt.2006.03.014.
Article
CAS
PubMed
Google Scholar
Iatrakis G, Zervoudis S, Saviolakis A, Troulos M, Antoniou E, Sarantaki A, Lykeridou K, Kourounis G: Women younger than 50 years with endometrial cancer. Eur J Gynaecol Oncol. 2006, 27: 399-400.
CAS
PubMed
Google Scholar
Semple RK, Chatterjee VK, O'Rahilly S: PPAR gamma and human metabolic disease. J Clin Invest. 2006, 116: 581-589. 10.1172/JCI28003.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lambert MT, Terrell JE, Copeland LA, Ronis DL, Duffy SA: Cigarettes, alcohol, and depression: characterizing head and neck cancer survivors in two systems of care. Nicotine Tob Res. 2005, 7: 233-241. 10.1080/14622200500055418.
Article
PubMed
Google Scholar
Ozlu T, Bulbul Y: Smoking and lung cancer. Tuberk Toraks. 2005, 53: 200-209.
PubMed
Google Scholar
Parimon T, Chien JW, Bryson CL, McDonell MB, Udris EM, Au DH: Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007, 175: 712-719. 10.1164/rccm.200608-1125OC.
Article
CAS
PubMed
Google Scholar
Caumes JL, Nousbaum JB, Bessaguet C, Faycal J, Robaszkiewicz M, Gouerou H: Epidemiology of hepatocellular carcinoma in Finistere Prospective study from June 2002 to May 2003. Gastroenterol Clin Biol. 2007, 31: 259-264.
Article
PubMed
Google Scholar
Fukuen S, Iwaki M, Yasui A, Makishima M, Matsuda M, Shimomura I: Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. J Biol Chem. 2005, 280: 23653-23659. 10.1074/jbc.M412113200.
Article
CAS
PubMed
Google Scholar